{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/16002"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/16002","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"The role of B cells in respiratory mucosal AdHu5Ag85A vaccine-induced immunity against tuberculosis","abstract":"Background: Mycobacterium tuberculosis (M.tb) is the causative pathogen of tuberculosis (TB) that is currently the leading cause of death from a bacterial infection. The only licensed vaccine against tuberculosis is the Bacille Calmette-Guérin (BCG) vaccine which fails to effectively protect against adult pulmonary TB. For this reason, efforts have focused on developing novel vaccine platforms to boost BCG-induced immunity. In this regard, a human adenovirus serotype 5 expressing the mycobacterial secreted antigen Ag85A (AdHu5Ag85A) vaccine developed in our lab has been evaluated in a phase I clinical trial. It was shown to boost and elicit lasting T cell responses in BCG-vaccinated volunteers. Although inducing a strong type I T cell mediated immunity by this vaccine is crucial for protection, the role of vaccine-induced B cell responses in protecting against M.tb infection remains poorly understood. Recent studies have shown B cells to contribute to protection by modulating T cell immunity during intracellular bacterial infections. Therefore, we hypothesize that AdHu5Ag85A vaccination also induces antigen-specific B cell responses and such B cells have an immunomodulatory effect on vaccine-induced T cell immunity. Methods: We compared antigen specific T cell and antibody responses in wild type (WT) Balb/c mice with B cell deficient (Jh-/-) mice after intranasal AdHu5Ag85A vaccination. Results: Interim data has demonstrated that AdHu5Ag85A induces antigen specific antibodies. In the absence of B cells, AdHu5Ag85A vaccination resulted in reduced Ag85A CD8+ T cells within the BAL compared to WT. Importantly, this correlated with impaired protection against pulmonary M.tb infection. The study is ongoing to examine the mechanisms by which B cells modulate these T cell responses. Conclusion: These data suggest that B cells are required for optimal protective T cell responses following AdHu5Ag85A respiratory mucosal vaccination against M.tb infection.","abstract_html":"Background: Mycobacterium tuberculosis (M.tb) is the causative pathogen of tuberculosis (TB) that is currently the leading cause of death from a bacterial infection. The only licensed vaccine against tuberculosis is the Bacille Calmette-Guérin (BCG) vaccine which fails to effectively protect against adult pulmonary TB. For this reason, efforts have focused on developing novel vaccine platforms to boost BCG-induced immunity. In this regard, a human adenovirus serotype 5 expressing the mycobacterial secreted antigen Ag85A (AdHu5Ag85A) vaccine developed in our lab has been evaluated in a phase I clinical trial. It was shown to boost and elicit lasting T cell responses in BCG-vaccinated volunteers. Although inducing a strong type I T cell mediated immunity by this vaccine is crucial for protection, the role of vaccine-induced B cell responses in protecting against M.tb infection remains poorly understood. Recent studies have shown B cells to contribute to protection by modulating T cell immunity during intracellular bacterial infections. Therefore, we hypothesize that AdHu5Ag85A vaccination also induces antigen-specific B cell responses and such B cells have an immunomodulatory effect on vaccine-induced T cell immunity. Methods: We compared antigen specific T cell and antibody responses in wild type (WT) Balb/c mice with B cell deficient (Jh-/-) mice after intranasal AdHu5Ag85A vaccination. Results: Interim data has demonstrated that AdHu5Ag85A induces antigen specific antibodies. In the absence of B cells, AdHu5Ag85A vaccination resulted in reduced Ag85A CD8+ T cells within the BAL compared to WT. Importantly, this correlated with impaired protection against pulmonary M.tb infection. The study is ongoing to examine the mechanisms by which B cells modulate these T cell responses. Conclusion: These data suggest that B cells are required for optimal protective T cell responses following AdHu5Ag85A respiratory mucosal vaccination against M.tb infection.","abstract_has_math":false,"creators":["Khera, Amandeep"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences (Molecular Virology and Immunology Program)","school":null,"contributors":[],"advisors":["Xing, Zhou"],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-11","date_published":"2014-11","updated_at":"2026-11-18T19:32:37Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/12412"],"render_values":[{"text":"https://doi.org/10.71548/12412","href":"https://doi.org/10.71548/12412","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/16002","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/16002","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F16002","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Xing, Zhou"]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences (Molecular Virology and Immunology Program)"]},{"key":"dc:creator","label":"Author","values":["Khera, Amandeep"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-10-01T20:16:15Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-10-01T20:16:15Z"]},{"key":"dc:date.issued","label":"Date","values":["2014-11"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/16002","https://doi.org/10.71548/12412"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background: Mycobacterium tuberculosis (M.tb) is the causative pathogen of tuberculosis (TB) that is currently the leading cause of death from a bacterial infection. The only licensed vaccine against tuberculosis is the Bacille Calmette-Guérin (BCG) vaccine which fails to effectively protect against adult pulmonary TB. For this reason, efforts have focused on developing novel vaccine platforms to boost BCG-induced immunity. In this regard, a human adenovirus serotype 5 expressing the mycobacterial secreted antigen Ag85A (AdHu5Ag85A) vaccine developed in our lab has been evaluated in a phase I clinical trial. It was shown to boost and elicit lasting T cell responses in BCG-vaccinated volunteers. Although inducing a strong type I T cell mediated immunity by this vaccine is crucial for protection, the role of vaccine-induced B cell responses in protecting against M.tb infection remains poorly understood. Recent studies have shown B cells to contribute to protection by modulating T cell immunity during intracellular bacterial infections. Therefore, we hypothesize that AdHu5Ag85A vaccination also induces antigen-specific B cell responses and such B cells have an immunomodulatory effect on vaccine-induced T cell immunity. Methods: We compared antigen specific T cell and antibody responses in wild type (WT) Balb/c mice with B cell deficient (Jh-/-) mice after intranasal AdHu5Ag85A vaccination. Results: Interim data has demonstrated that AdHu5Ag85A induces antigen specific antibodies. In the absence of B cells, AdHu5Ag85A vaccination resulted in reduced Ag85A CD8+ T cells within the BAL compared to WT. Importantly, this correlated with impaired protection against pulmonary M.tb infection. The study is ongoing to examine the mechanisms by which B cells modulate these T cell responses. Conclusion: These data suggest that B cells are required for optimal protective T cell responses following AdHu5Ag85A respiratory mucosal vaccination against M.tb infection."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["The role of B cells in respiratory mucosal AdHu5Ag85A vaccine-induced immunity against tuberculosis"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Xing, Zhou"],"dc:contributor.department":["Medical Sciences (Molecular Virology and Immunology Program)"],"dc:creator":["Khera, Amandeep"],"dc:date.accessioned":["2014-10-01T20:16:15Z"],"dc:date.available":["2014-10-01T20:16:15Z"],"dc:date.issued":["2014-11"],"dc:description.abstract":["Background: Mycobacterium tuberculosis (M.tb) is the causative pathogen of tuberculosis (TB) that is currently the leading cause of death from a bacterial infection. The only licensed vaccine against tuberculosis is the Bacille Calmette-Guérin (BCG) vaccine which fails to effectively protect against adult pulmonary TB. For this reason, efforts have focused on developing novel vaccine platforms to boost BCG-induced immunity. In this regard, a human adenovirus serotype 5 expressing the mycobacterial secreted antigen Ag85A (AdHu5Ag85A) vaccine developed in our lab has been evaluated in a phase I clinical trial. It was shown to boost and elicit lasting T cell responses in BCG-vaccinated volunteers. Although inducing a strong type I T cell mediated immunity by this vaccine is crucial for protection, the role of vaccine-induced B cell responses in protecting against M.tb infection remains poorly understood. Recent studies have shown B cells to contribute to protection by modulating T cell immunity during intracellular bacterial infections. Therefore, we hypothesize that AdHu5Ag85A vaccination also induces antigen-specific B cell responses and such B cells have an immunomodulatory effect on vaccine-induced T cell immunity. Methods: We compared antigen specific T cell and antibody responses in wild type (WT) Balb/c mice with B cell deficient (Jh-/-) mice after intranasal AdHu5Ag85A vaccination. Results: Interim data has demonstrated that AdHu5Ag85A induces antigen specific antibodies. In the absence of B cells, AdHu5Ag85A vaccination resulted in reduced Ag85A CD8+ T cells within the BAL compared to WT. Importantly, this correlated with impaired protection against pulmonary M.tb infection. The study is ongoing to examine the mechanisms by which B cells modulate these T cell responses. Conclusion: These data suggest that B cells are required for optimal protective T cell responses following AdHu5Ag85A respiratory mucosal vaccination against M.tb infection."],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.uri":["http://hdl.handle.net/11375/16002","https://doi.org/10.71548/12412"],"dc:language.iso":["en"],"dc:title":["The role of B cells in respiratory mucosal AdHu5Ag85A vaccine-induced immunity against tuberculosis"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:32:37Z"}